References
- Adalbert, J.-R., and A.-M. Ilyas. 2022. A focus on the future of opioid prescribing: Implementation of a virtual opioid and pain management module for medical students. BMC Medical Education 22 (1):18. doi:10.1186/s12909-021-03058-z.
- Barnett, B.-S., M. Arakelian, D. Beebe, J. Ontko, C. Riegal, W.-O. Siu, J. Weleff, and H.-G. Pope. 2023. American psychiatrists’ opinions about classic Hallucinogens and their potential therapeutic applications: A 7-year follow-up survey. Psychedelic Medicine. doi:10.1089/psymed.2023.0036. 2 1 1–9
- Barnett, B.-S., Y. Beaussant, F. King, and R. Doblin. 2022. Psychedelic knowledge and opinions in psychiatrists at two professional conferences: An exploratory survey. Journal of Psychoactive Drugs 54 (3):269–77. doi:10.1080/02791072.2021.1957183.
- Barnett, B.-S., W.-O. Siu, and H.-G. Pope. 2018. A survey of American psychiatrists’ attitudes toward classic hallucinogens. Journal Nervous and Mental Disease 206 (6):476–80.
- Boehnke, K.-F., K. Cox, C. Weston, M. Herberholz, N. Glynos, N. Kolbman, C.-W. Fields, J. Barron, and D.-J. Kruger. 2023. Slouching towards engagement: Interactions between people using psychedelics naturalistically and their healthcare providers. 2023. Frontiers in Psychiatry 14. doi:10.3389/fpsyt.2023.1224551.
- da Costa, S.-C., T. Oesterle, T.-A. Rummans, E. Richelson, and M. Gold. 2022. Psychedelic drugs for psychiatric disorders. Journal of the Neurological Sciences 440:120332. doi:10.1016/j.jns.2022.120332.
- Davis, A.-K., G. Agin-Liebes, M. España, B. Pilecki, and J.-B. Luoma. 2021. Attitudes and beliefs about the therapeutic use of psychedelic drugs among psychologists in the United States. Journal of Psychoactive Drugs 54 (4):309–18. doi:10.1080/02791072.2021.1971343.
- Glynos, N.-G., C.-W. Fields, J. Barron, M. Herberholz, D.-J. Kruger, and K.-F. Boehnke. 2022. Naturalistic psychedelic use: A world apart from clinical care. Journal of Psychoactive Drugs 55 (4):379–88. doi:10.1080/02791072.2022.2108356.
- Goodwin, G.-M., S.-T. Aaronson, O. Alvarez, P.-C. Arden, A. Baker, J.-C. Bennett, C. Bird, R.-E. Blom, C. Brennan, D. Brusch, et al. 2022. Single-dose psilocybin for a treatment-resistant episode of major depression. New England Journal of Medicine 387(18):1637–48. doi:10.1056/NEJMoa2206443.
- Lee, Y.-J. 2022. Johns Hopkins, Yale, and NYU are teaming up to tackle a key bottleneck that will arise as psychedelics come to market. Last Modified March 10, 2022. Accessed April 26, 2023. https://www.businessinsider.com/psychedelics-psychiatrist-training-program-johns-hopkins-nyu-yale-university-2022-3.
- Levin, A., P.-B. Nagib, S. Deiparine, T. Gao, J. Mitchell, and A.-K. Davis. 2022. Inconsistencies between national drug policy and professional beliefs about psychoactive drugs among psychiatrists in the United States. International Journal of Drug Policy 108:103816. doi:10.1016/j.drugpo.2022.103816.
- Lowe, H., N. Toyang, B. Steele, J. Grant, A. Ali, L. Gordon, and W. Ngwa. 2022. Psychedelics: Alternative and potential therapeutic options for treating mood and anxiety disorders. 2022. Molecules 27 (8):252. doi:10.3390/molecules27082520.
- Luoma, J.-B., C. Chwyl, G.-J. Bathje, A.-K. Davis, and R. Lancelotta. 2020. A meta-analysis of placebo-controlled trials of psychedelic-assisted therapy. Journal of Psychoactive Drugs 52 (4):289–99. doi:10.1080/02791072.2020.1769878.
- Mitchell, J.-M., M. Bogenschutz, A. Lilienstein, C. Harrison, S. Kleiman, K. Parker-Guilbert, G.-M. Ot’alora, W. Garas, C. Paleos, I. Gorman, et al. 2021. MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine 27 (6):1025–33. doi:10.1038/s41591-021-01336-3.
- Nichols, D.-E., and E. L. Barker. 2016. Psychedelics. Pharmacology Reviews 68 (2):264–355. doi:10.1124/pr.115.011478.
- O’Donnell, K.-C., D.-E. Roberts, T.-H.-W. Ching, G. Glick, N. Goldway, N. Gukasyan, J. Hokansen, B. Kelmendi, S. Ross, M.-E. Yaden, et al. 2023. Letter to the editor: What is in a name? The many meanings of “psychedelic”. Psychedelic Medicine 1 (4):187–89. doi:10.1089/psymed.2023.0011. ahead of print
- Prueitt, W.-L., and J. Sloshower. 2023. Psychedelic medicine: Creating an introductory course for mental health professionals and trainees. Academic Psychiatry 47 (1):74–77. doi:10.1007/s40596-022-01662-9.
- Reiff, C.-M., E.-E. Richman, C.-B. Nemeroff, L.-L. Carpenter, A.-S. Widge, C.-I. Rodriguez, N. H. Kalin, W. M. McDonald, and Work Group on Biomarkers and Novel Treatments, a Division of the American Psychiatric Association Council of Research. 2020. Psychedelics and psychedelic-assisted psychotherapy. The American Journal of Psychiatry 177 (5):391–410. doi:10.1176/appi.ajp.2019.19010035.
- Walsh, C.-A., L. Gorfinkel, D. Shmulewitz, M. Stohl, and D.-S. Hasin. 2023. Use of lysergic acid diethylamide by major depression status. JAMA Psychiatry 81 (1):89. doi:10.1001/jamapsychiatry.2023.3867.
- Winstock, A.-R., C. Timmerman, E. Davids, L.-J. Maier, A. Zhuparris, J.-A. Ferris, M.-J. Barratt, and K.-P.-C. Kuypers. 2020. Global Drug Survey (GDS) 2020 Psychedelics key findings report.
- Yockey, R.-A., R.-A. Vidourek, and K.-A. King. 2020. Trends in LSD use among US adults: 2015-2018. Drug and Alcohol Dependence 212:108071. doi:10.1016/j.drugalcdep.2020.108071.